BACKGROUND: To assess whether differences of biochemical recurrence after radical prostatectomy exist between prostate cancers located in the transition zone (TZ) and peripheral zone (PZ). METHODS: The 5-year biochemical recurrence rate of 307 patients was evaluated. A serum prostate specific antigen (PSA) level > or =0.1 ng/ml was defined as biochemical failure. Cancers were characterized by the location of the largest tumor area as TZ or PZ cancers. Pure PZ cancers were matched to TZ cancers by comparable pathological tumor stage, Gleason score, and surgical margin status. RESULTS: In 63 (20.5%) patients the largest tumor area was located in the TZ. A Kaplan-Meier analysis of the matched pairs calculated an 80% actuarial cure rate of TZ cancers compared to 89% of pure PZ cancers (log-rank test P = 0.742). CONCLUSIONS: TZ and pure PZ cancers matched by comparable pathological tumor stage, Gleason score, and surgical margin status showed no statistical difference in regard to biochemical cure following radical prostatectomy. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: To assess whether differences of biochemical recurrence after radical prostatectomy exist between prostate cancers located in the transition zone (TZ) and peripheral zone (PZ). METHODS: The 5-year biochemical recurrence rate of 307 patients was evaluated. A serum prostate specific antigen (PSA) level > or =0.1 ng/ml was defined as biochemical failure. Cancers were characterized by the location of the largest tumor area as TZ or PZ cancers. Pure PZ cancers were matched to TZ cancers by comparable pathological tumor stage, Gleason score, and surgical margin status. RESULTS: In 63 (20.5%) patients the largest tumor area was located in the TZ. A Kaplan-Meier analysis of the matched pairs calculated an 80% actuarial cure rate of TZ cancers compared to 89% of pure PZ cancers (log-rank test P = 0.742). CONCLUSIONS: TZ and pure PZ cancers matched by comparable pathological tumor stage, Gleason score, and surgical margin status showed no statistical difference in regard to biochemical cure following radical prostatectomy. Copyright 2003 Wiley-Liss, Inc.
Authors: J Joy Lee; I-Chun Thomas; Rosalie Nolley; Michelle Ferrari; James D Brooks; John T Leppert Journal: Prostate Date: 2014-10-18 Impact factor: 4.104
Authors: Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena Journal: Nat Rev Urol Date: 2021-10-19 Impact factor: 14.432
Authors: Ghiam Yamin; Natalie M Schenker-Ahmed; Ahmed Shabaik; Dennis Adams; Hauke Bartsch; Joshua Kuperman; Nathan S White; Rebecca A Rakow-Penner; Kevin McCammack; J Kellogg Parsons; Christopher J Kane; Anders M Dale; David S Karow Journal: Clin Cancer Res Date: 2016-06-01 Impact factor: 12.531
Authors: Georgios Theophilou; Kássio M G Lima; Matthew Briggs; Pierre L Martin-Hirsch; Helen F Stringfellow; Francis L Martin Journal: Sci Rep Date: 2015-08-27 Impact factor: 4.379